Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
CytomX Therapeutics Inc(CTMX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CTMX
09/28/2026: CTMX (3-star) is currently NOT-A-BUY. Pass it for now.
CytomX Therapeutics is a clinical-stage biotechnology company that utilizes its proprietary Probody platform to develop tumor-targeted antibody therapeutics. The company's primary strength lies in its specialized R&D capabilities and its ability to secure high-value partnerships with major pharmaceutical players, which help validate its technology and provide critical funding. The core investment story centers on the success of its next-generation bispecific and ADC programs. However, investors must weigh these prospects against high execution, regulatory, and competitive risks, as well as the volatility inherent in clinical-stage biotech. The stock is most suitable for risk-tolerant investors looking for long-term growth exposure, with key developments in clinical trial readouts to monitor.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to biotechnology innovation but lacks current product revenue. |
| Momentum investor | Mixed fit | Momentum is highly conditional on positive clinical data readouts or major partnership announcements. |
| Value investor | Weak fit | The lack of earnings and reliance on R&D pipeline valuation makes traditional value metrics inapplicable. |
| Dividend investor | Weak fit | The company does not pay dividends and retains all capital for research and operations. |
| Low-risk investor | Weak fit | Clinical-stage biotechnology stocks are inherently volatile and subject to high binary risk. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock price is highly sensitive to clinical trial results and partnership updates. |
| Valuation risk | High | Valuations are speculative and rely heavily on long-term projections of unproven drug candidates. |
| Competition risk (Large pharma) | Medium / high | CytomX must compete for clinical resources and talent against much larger, better-funded incumbents. |
| Business quality | Medium | While the technology is novel, the company has not yet proven a sustainable, profitable commercial business model. |
| Dividend income | Low / none | The company does not generate the cash flow required for dividends. |
| Execution risk | High | Success depends entirely on the technical and regulatory execution of complex drug development programs. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 111.22% | Avg. Invested days 34 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 588.33M USD | Price to earnings Ratio - | 1Y Target Price 12.25 |
Price to earnings Ratio - | 1Y Target Price 12.25 | ||
Volume (30-day avg) 3.9M shares | Beta 2.14 | 52 Weeks Range 2.60 - 8.21 | Updated Date 09/27/2026 |
52 Weeks Range 2.60 - 8.21 | Updated Date 09/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Collaboration and Licensing | Milestone payments, upfront fees, and research funding from pharmaceutical partners. | Revenue is earned when the company hits specific technical milestones with its drug discovery partners. |
Valuation
Trailing PE - | Forward PE 14.2 | Enterprise Value 282.27M | Price to Sales(TTM) 32.14 |
Enterprise Value 282.27M | Price to Sales(TTM) 32.14 | ||
Enterprise Value to Revenue 15.42 | Enterprise Value to EBITDA 8.72 | Shares Outstanding 217.90M | Shares Floating 179.76M |
Shares Outstanding 217.90M | Shares Floating 179.76M | ||
Percent Insiders 0.57 | Percent Institutions 104.09 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About CytomX Therapeutics Inc
Exchange NASDAQ | Headquarters South San Francisco, CA, United States | ||
IPO Launch date 2015-10-08 | Chairman & CEO Dr. Sean A. McCarthy DPHIL | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.cytomx.com |
Full time employees 69 | Website https://www.cytomx.com | ||
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.